Evommune, Inc. Announces Late-Breaker Phase 2a Data Presentation at EADV 2026

What Happened

• Evommune, Inc. filed a Form 8-K on September 23, 2026 (Item 7.01) to disclose a press release titled "Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress." The filing furnishes that press release as Exhibit 99.1 (Item 9.01) and was signed by Luis Peña, President and CEO.
• The press release announces a late‑breaker presentation of Phase 2a clinical data for Evommune’s investigational candidate EVO301 in atopic dermatitis at the EADV 2026 Congress. The 8-K furnishes the announcement but does not itself contain the full clinical data.

Key Details

• Filing date: September 23, 2026 (Form 8-K, Item 7.01 Regulation FD Disclosure).
• Event: Late‑breaker presentation of Phase 2a EVO301 data at the European Academy of Dermatology & Venereology (EADV) 2026 Congress.
• Document furnished: Press release included as Exhibit 99.1 in the 8-K.
• Company signatory: Luis Peña, President and Chief Executive Officer.

Why It Matters

• A “late‑breaker” designation at a major medical congress typically signals the data are considered timely or of special interest to the dermatology community—investors should watch for the actual presentation, slides, or publication to assess efficacy/safety outcomes.
• The announcement increases visibility for Evommune’s EVO301 program; while the 8-K itself does not provide results, the forthcoming conference presentation may drive news flow and investor reactions once the data are released.